Literature DB >> 36104417

The destructive power of PROTACs could tackle prostate cancer.

Simon Makin.   

Abstract

Entities:  

Keywords:  Biotechnology; Cancer; Therapeutics

Mesh：

Substances：

Year:  2022        PMID： 36104417     DOI： 10.1038/d41586-022-02860-z

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   69.504


× No keyword cloud information.
  3 in total

1.  Catalytic in vivo protein knockdown by small-molecule PROTACs.

Authors:  Daniel P Bondeson; Alina Mares; Ian E D Smith; Eunhwa Ko; Sebastien Campos; Afjal H Miah; Katie E Mulholland; Natasha Routly; Dennis L Buckley; Jeffrey L Gustafson; Nico Zinn; Paola Grandi; Satoko Shimamura; Giovanna Bergamini; Maria Faelth-Savitski; Marcus Bantscheff; Carly Cox; Deborah A Gordon; Ryan R Willard; John J Flanagan; Linda N Casillas; Bartholomew J Votta; Willem den Besten; Kristoffer Famm; Laurens Kruidenier; Paul S Carter; John D Harling; Ian Churcher; Craig M Crews
Journal:  Nat Chem Biol       Date:  2015-06-10       Impact factor: 15.040

2.  Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.

Authors:  Steven Kregel; Chao Wang; Xin Han; Lanbo Xiao; Ester Fernandez-Salas; Pushpinder Bawa; Brooke L McCollum; Kari Wilder-Romans; Ingrid J Apel; Xuhong Cao; Corey Speers; Shaomeng Wang; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2020-01-10       Impact factor: 5.715

3.  Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance.

Authors:  Jemilat Salami; Shanique Alabi; Ryan R Willard; Nick J Vitale; Jing Wang; Hanqing Dong; Meizhong Jin; Donald P McDonnell; Andrew P Crew; Taavi K Neklesa; Craig M Crews
Journal:  Commun Biol       Date:  2018-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.